Three new pharmaceutical products were unveiled by the Golrang Pharmaceutical Investment Group during the 10th Iran Pharma International Exhibition.
According to the Public Relations Department of Golrang Pharmaceutical Group, the unveiling ceremony took place on the sidelines of the 10th Iran Pharma International Exhibition of Pharmaceuticals and Related Industries (Iran Pharma 2025), attended by Mr. Sezavar, Executive Vice President of Golrang Industrial Group; Mr. Ashofteh, CEO of Golrang Pharmaceutical Group; Mr. Soleimanjahi, Secretary of the Syndicate of Human Pharmaceutical Industries; Dr. Masoumeh Khan Ahmadi, Director General of Technology at the Ministry of Science; Mr. Rastgari, Director General of Innovative Companies at the Vice-Presidency for Science and Technology; along with deputy executives and CEOs of Golrang’s subsidiary companies.
Attvanse (Lisdexamfetamine Mesylate) – A Novel Step in ADHD and BED Treatment
Mr. Ghasemali Ashofteh, CEO and Vice Chairman of the Board of Golrang Pharmaceutical Investment Company, began the ceremony by introducing three new products developed by the group’s R&D teams.
He stated:
“We are proud to introduce three new products to the pharmaceutical community and patients at this prestigious international event. These are the result of extensive research and collaboration among our subsidiaries and mark a new step forward in advanced treatment solutions.”
The first product unveiled was Attvanse, the trade name for Lisdexamfetamine Mesylate, developed by Faran Shimi, a knowledge-based company subsidiary to the Golrang Pharmaceutical Group.
Lisdexamfetamine is a prodrug of dextroamphetamine with sympathomimetic activity, enhancing the release of dopamine and norepinephrine from presynaptic neurons while inhibiting their reuptake. This mechanism increases catecholamine levels in the synaptic cleft—helping alleviate symptoms of Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED).
Available in 10, 20, 30, 50, and 70 mg dosages, Etunes significantly improves concentration and behavioral control by balancing neurotransmitter activity.
Mr. Ashofteh emphasized that introducing Attvanse is part of Faran Shimi’s strategic plan to expand modern neurological treatments in Iran’s domestic pharmaceutical market.
Inbresta(Palbociclib) – A New Approach to Breast Cancer Therapy
The second product, Inbresta(Palbociclib) 100/125 mg, is manufactured by Abian Pharmed, another knowledge-based company under the Golrang Group.
Mr. Ashofteh explained:
“This drug selectively inhibits CDK4 and CDK6, key kinases involved in cell cycle progression through the G1/S transition. By blocking CDK4/6 activity, Albusiclib effectively halts the proliferation of breast cancer cells.”
The oral capsule formulation, to be taken with food, is prescribed for hormone receptor-positive (HR+) and HER2-negative advanced or metastatic breast cancer.
He noted that Abian Pharmed’s entry into the field of oncology and immunosuppressive drugs marks a major step toward domestic self-sufficiency and export growth. The company currently has over 20 oncology products in its development pipeline, including Inbresta, used as a first-line treatment for breast cancer.
ACTiAID for Women – Enhancing Female Fertility Naturally
The third product unveiled was ACTiAID for Women, a fertility-support supplement developed by Abian Darou.
This formulation combines Myo-inositol and D-Chiro-inositol in a precise 40:1 ratio, with a pleasant lemon flavor. It helps improve oocyte quality, regulate menstrual cycles, reduce insulin resistance, and enhance IVF success rates.
Ashofteh emphasized:
“ACTiAID for Women represents our ongoing commitment to supporting women’s reproductive health with scientifically validated and safe nutritional supplements.”
Commitment to Innovation and Health
At the end of the Unveiling ceremony , Engineer Ashofteh stated:
“The unveiling of these three new products reflects Golrang Pharmaceutical Group’s dedication to innovation and knowledge-based development. We will continue investing in research and technology to meet patients’ therapeutic needs and contribute meaningfully to improving public health.”
